Laurus Labs Ltd
NSE:LAURUSLABS

Watchlist Manager
Laurus Labs Ltd Logo
Laurus Labs Ltd
NSE:LAURUSLABS
Watchlist
Price: 665.9 INR -0.06%
Market Cap: 359.3B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LAURUSLABS stock under the Base Case scenario is 695.85 INR. Compared to the current market price of 665.9 INR, Laurus Labs Ltd is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAURUSLABS Relative Value
Base Case
695.85 INR
Undervaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.5
P/S
P/S
Price to Sales
6.5
vs History
6
vs Industry
21
Median 3Y
4.7
Median 5Y
4.7
Industry
2.5
Forward
5.4
More Details
100.2
P/E
P/E
Price to Earnings
100.2
vs History
23
vs Industry
1
Median 3Y
57.9
Median 5Y
33.5
Industry
21.1
Forward
62.3
More Details
59.7
P/OCF
P/OCF
Price to OCF
59.7
vs History
9
vs Industry
3
Median 3Y
32.7
Median 5Y
33.7
Industry
16.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
2
Median 3Y
124.5
Median 5Y
111.3
Industry
23.7
More Details
8
P/B
P/B
Price to Book Value
8
vs History
31
vs Industry
8
Median 3Y
5.9
Median 5Y
6.9
Industry
2.1
More Details
6.6
EV/S
EV/S
Enterprise Value to Sales
6.6
vs History
6
vs Industry
21
Median 3Y
4.8
Median 5Y
4.9
Industry
2.6
Forward
5.5
More Details
11.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.9
vs History
12
vs Industry
18
Median 3Y
9.3
Median 5Y
9.3
Industry
5.1
More Details
34.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
34.6
vs History
6
vs Industry
9
Median 3Y
22.2
Median 5Y
19.5
Industry
12.4
Forward
24.9
More Details
58.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
58.4
vs History
17
vs Industry
5
Median 3Y
31.9
Median 5Y
23.3
Industry
15.7
Forward
36.4
More Details
60.6
EV/OCF
EV/OCF
Enterprise Value to OCF
60.6
vs History
9
vs Industry
4
Median 3Y
33.3
Median 5Y
34.5
Industry
14.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
7
Median 3Y
76.6
Median 5Y
86.8
Industry
17.1
More Details
4.4
EV/IC
EV/IC
Enterprise Value to IC
4.4
vs History
38
vs Industry
17
Median 3Y
3.4
Median 5Y
4
Industry
1.8
More Details

Multiples Across Competitors

LAURUSLABS Competitors Multiples
Laurus Labs Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Laurus Labs Ltd
NSE:LAURUSLABS
359.3B INR 6.5 100.2 34.6 58.4
US
Eli Lilly and Co
NYSE:LLY
730.4B USD 14.9 65.8 35.3 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 4.1 16.7 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.1 13.2 15.2
CH
Roche Holding AG
SIX:ROG
207.2B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
186.3B CHF 4.3 17.8 10.5 14.1
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
201.7B USD 3.2 11.6 8.6 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
136.6B USD 2.2 17.3 7.5 10.5
P/E Multiple
Earnings Growth PEG
IN
Laurus Labs Ltd
NSE:LAURUSLABS
Average P/E: 33.5
100.2
41%
2.4
US
Eli Lilly and Co
NYSE:LLY
65.8
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.7
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Laurus Labs Ltd
NSE:LAURUSLABS
Average EV/EBITDA: 397.2
34.6
26%
1.3
US
Eli Lilly and Co
NYSE:LLY
35.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Laurus Labs Ltd
NSE:LAURUSLABS
Average EV/EBIT: 1 702.6
58.4
36%
1.6
US
Eli Lilly and Co
NYSE:LLY
38.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.2
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.1
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.4
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1

See Also

Summary
LAURUSLABS intrinsic value, competitors valuation, and company profile.
DCF Valuation
LAURUSLABS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LAURUSLABS stock valuation using valuation multiples.
Wall Street Estimates
LAURUSLABS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LAURUSLABS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.